MedPath

Prophylactic Continuous Positive Airway Pressure (CPAP) in Delivery Room, in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial

Not Applicable
Completed
Conditions
Transient Tachypnea
Interventions
Other: Prophylactic CPAP Administration
Registration Number
NCT01082900
Lead Sponsor
New York Hospital Queens
Brief Summary

Transient Tachypnea of the Newborn (TTN) is a disorder of delayed clearance of lung liquid and a common cause of admission of full term infants and late pre term infants (34 to 36 weeks) to Neonatal Intensive Care Units (NICU). Both late preterm gestational age at delivery, and mode of delivery are considered risk factors for TTN. The investigators hypothesize that CPAP administered prophylactically in the Delivery Room via a T piece based infant resuscitator Neopuff, to neonates at increased risk for TTN, would decrease the incidence of TTN and thus decrease the need for hospitalization in the NICU. This is a pilot study to evaluate the prophylactic administration of CPAP in the Delivery Room towards prevention of TTN and it's effects on natriuretic peptides.The study will be conducted as a randomized control trial after obtaining informed consents from the parents of eligible infants. Infants will be randomized to receive either experimental treatment (prophylactic CPAP) or standardized care.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
138
Inclusion Criteria
  • Babies born to mothers via elective CS: elective CS defined as planned CS in the absence of Labor.
  • Late preterm infants (34 1/7 to 36 6/7 weeks gestational age)
Exclusion Criteria
  • Presence of any of the risk factors for neonatal sepsis such as Prolonged Rupture of Membranes for ≥18 hours (PROM), maternal fever, maternal chorioamnionitis or positive maternal GBS colonization

  • Need for use of PPV for perinatal depression or other indications

  • Presence of any of the following

    • congenital malformations (diagnosed prenatally)
    • chromosomal anomalies (diagnosed prenatally)
    • congenital heart disease diagnosed by fetal echocardiography.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
No InterventionProphylactic CPAP AdministrationProvision of standard care in the Delivery Room
Prophylactic CPAP interventionProphylactic CPAP AdministrationBabies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
Primary Outcome Measures
NameTimeMethod
Need for admissions to NICU secondary to TTN24 hours
Measure of incidence of TTN24 hours
Secondary Outcome Measures
NameTimeMethod
levels of plasma brain natriuretic peptide compared24 hours

* Duration of tachypnea

* Duration of oxygen therapy

* Length of hospital (NICU) stay

Trial Locations

Locations (1)

New York Hospital Queens

🇺🇸

Flushing, New York, United States

© Copyright 2025. All Rights Reserved by MedPath